IDENTIFICATION OF POSSIBLE INHIBITORS OF CORONAVIRUS HEMAGGLUTININ-ESTERASE THROUGH MOLECULAR DOCKING, MOLECULAR DYNAMICS SIMULATION AND BINDING FREE ENERGY CALCULATION

Main Article Content

NEHA BHATI
ANAMIKA CHAUDHARY

Abstract

Vaccines are urgently needed to control the 2019 novel coronavirus disease (COVID-19) and help restore normal conditions before the pandemic. The hemagglutinin-esterase belongs to viral envelope glycoproteins family that facilitates reversible binding to O-acetylated sialic acids as a result of acting as lectins as well as receptor-destroying enzymes. Associated hemagglutinin-esterase take place in influenza C, toro-, besides coronaviruses. At this point, we initiate the crystal assembly of a coronavirus hemagglutinin-esterase in composite with its receptor through RCSB-PDB (id 5n11). We prepared this protein for docking more inhibitors with Autodock 4.0 by adding polar hydrogen and Kollman charges. We described its active site through Dog Site Scorer server and found Bovine corona virus is very near to our target protein with the help of phylogenetic analysis through MEGA-X software and proposed that we can do drug designing on Bovine coronavirus too for clinical trial on animal.

Keywords:
Coronavirus, potential inhibitors, molecular docking, molecular dynamics

Article Details

How to Cite
BHATI, N., & CHAUDHARY, A. (2021). IDENTIFICATION OF POSSIBLE INHIBITORS OF CORONAVIRUS HEMAGGLUTININ-ESTERASE THROUGH MOLECULAR DOCKING, MOLECULAR DYNAMICS SIMULATION AND BINDING FREE ENERGY CALCULATION. UTTAR PRADESH JOURNAL OF ZOOLOGY, 42(19), 17-23. Retrieved from http://mbimph.com/index.php/UPJOZ/article/view/2457
Section
Original Research Article

References

Shirato K, Kawase M, Matsuyama S. Wild-type human coronaviruses prefer cell-surface TMPRSS2 to endosomal cathepsins for cell entry. Virology. 2018;517:9–15.

De Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat. Rev. Microbiol. 2016;14(8):523–534.

Chan JFW, Yuan S, Kok KH, To KKW, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514–523.

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223): 507–513.

Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. China medical treatment expert group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020;382(18):1708–1720.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.

Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N. Engl. J. Med. 2020;382(13):1199–1207.

Tian S, Hu N, Lou J, Chen K, Kang X, Xiang Z, et al. Characteristics of COVID-19 infection in Beijing. J. Infect. 2020;80(4): 401–406.

Paderno A, Schreiber A, Grammatica A, Raffetti E, Tomasoni M, Gualtieri T, et al. Smell and taste alterations in Covid-19: a cross-sectional analysis of different cohorts. Int. Forum Allergy Rhinol; 2020. DOI: 10.1002/alr.22610.

Sedaghat AR, Gengler I, Speth MM. Olfactory dysfunction: A highly prevalent symptom of COVID-19 with public health significance. Otolaryngol. Head. Neck Surg; 2020. DOI:10.1177/0194599820926464. 194599820926464.

Yan CH, Faraji F, Prajapati DP, Boone CE, DeConde AS. Association of chemosensory dysfunction and Covid-19 in patients presenting with influenza-like symptoms. Int. Forum Allergy Rhinol; 2020. DOI: 10.1002/alr.22579.

Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, Ji R, Wang H, Wang Y, Zhou Y. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int. J. Infect. Dis. 2020;94:91–95. DOI: 10.1016/j.ijid.2020.03.017.

Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat. Rev. Immunol; 2020. DOI: 10.1038/s41577-020-0331-4.

Yang X, Yu Y, Xu J, Shu H, Xia JA, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med. 2020; 8(5):475–481.

Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, Wang T, Zhang X, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Invest. 2020; 130(5):2620–2629.

Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin. Infect. Dis; 2020. DOI: 10.1093/cid/ciaa248.

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062.

Perrone LA, Plowden JK, García-Sastre A, Katz JM, Tumpey TM. H5N1 and 1918 pandemic influenza virus infection results in early and excessive infiltration of macrophages and neutrophils in the lungs of mice. PLoS Pathog. 2008;4. DOI: 10.1371/journal.ppat.1000115.

D’Elia RV, Harrison K, Oyston PC, Lukaszewski RA, Clark GC. Targeting the ‘cytokine storm’ for therapeutic benefit. Clin. Vaccine Immunol. 2013;20(3):319–327.

Meduri GU, Kohler G, Headley S, Tolley E, Stentz F, Postlethwaite A. Inflammatory cytokines in the BAL of patients with ARDS. Persistent elevation over time predicts poor outcome. Chest. 1995;108:1303–1314.

Bouros D, Alexandrakis MG, Antoniou KM, Agouridakis P, Pneumatikos I, Anevlavis S, Pataka A, Patlakas G, Karkavitsas N, Kyriakou D. The clinical significance of serum and bronchoalveolar lavage inflammatory cytokines in patients at risk for Acute Respiratory Distress Syndrome. BMC Pulm. Med. 2004; 4:6. DOI: 10.1186/1471-2466-4-6.

Yao Z, Zheng Z, Wu K, Junhua Z. Immune environment modulation in pneumonia patients caused by coronavirus: SARS-CoV, MERS-CoV and SARS-CoV-2. Aging (Albany NY) 2020;12(9):7639–7651. DOI: 10.18632/aging.103101.

Xiong Y, Liu Y, Cao L, Wang D, Guo M, Jiang A. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerg. Microbes Infect. 2020; 9(1):761–770. DOI: 10.1080/22221751.2020.1747363.

Wong CK, Lam CW, Wu AK, Ip WK, Lee NL, Chan IH, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin. Exp. Immunol. 2004;136:95–103. DOI: 10.1111/j.1365-2249.2004.02415.x.

Mahallawi WH, Khabour OF, Zhang Q, Makhdoum HM, Suliman BA. MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile. Cytokine. 2018;104:8–13. DOI: 10.1016/j.cyto.2018.01.025.